All In Biotech

NDA 017963 · Validus Pharms

Lopressor

Metoprolol Tartrate · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Dec 22, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1978

Aug 7, 1978

Approved uses

4

Original approval plus efficacy supplements

Registered trials

302

56 Phase 3, 19 recruiting

FAERS reports

86,471

59,888 serious, 9,924 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 14, 2023.

1 IND ICATIONS AND USAGE LOPRESSOR is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension LOPRESSOR is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other...

Mechanism: Metoprolol is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade. Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction. The relative beta 1...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 27, 1986 Supplement 34 · Efficacy
  • Mar 30, 1984 Supplement 24 · Efficacy
  • Apr 12, 1983 Supplement 28 · Efficacy
  • Aug 7, 1978 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • LOPRESSOR · METOPROLOL TARTRATE 50MG · TABLET, ORAL · Prescription · TE AB
  • LOPRESSOR · METOPROLOL TARTRATE 100MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Metoprolol" as an intervention, any sponsor and status, largest first.

All 302 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue5,878
  • nausea5,108
  • dyspnoea5,035
  • diarrhoea5,014
  • dizziness3,953
  • death3,874
  • drug ineffective3,796
  • pain3,713
  • asthenia3,684
  • headache3,255
  • fall3,119
  • myocardial infarction3,041

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,399
20051,811
20062,035
20071,422
20083,265
20092,706
20103,627
20115,835
20125,503
20132,009
20143,994
20154,233
20165,398
20175,594
20185,556
20195,428
20204,735
20213,713
20223,691
20233,488
20243,430
20254,141
20263,456

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lopressor (Metoprolol Tartrate)

2024 spending

$310K

Beneficiaries

257

901 claims

Per beneficiary

$1,204

$2.67 per unit

View as table
YearSpending
2020$518,195
2021$487,155
2022$459,116
2023$369,969
2024$309,517

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,994 on PubMed

Sponsor: Validus Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.